PCM
RLAY icon

Prelude Capital Management’s Relay Therapeutics RLAY Stock Holding History

Prelude Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$616K Buy
+61,899
New +$554K 0.05% 434
2025
Q4 		– Sell
-19,700
Closed -$103K – 1518
2025
Q3 		$103K Buy
19,700
+3,100
+19% +$11.8K 0.01% 1052
2025
Q2 		$57.4K Sell
16,600
-4,600
-22% -$13.7K 0.01% 955
2025
Q1 		$55.5K Sell
21,200
-275,965
-93% -$1.08M ﹤0.01% 1090
2024
Q4 		$1.22M Buy
297,165
+187,253
+170% +$1.02M 0.08% 326
2024
Q3 		$778K Buy
+109,912
New +$821K 0.05% 458

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prelude Capital Management's RLAY Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Relay Therapeutics (RLAY) in Q1 2026: 61,899 shares worth $616K. The stake represents 0.05% of the portfolio and ranks #434 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in RLAY as recently as Q3 2025.

Prelude Capital Management first reported a position in RLAY in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.22M in Q4 2024. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Prelude Capital Management held 61,899 shares of Relay Therapeutics worth $616K as of Q1 2026.
  • Relay Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • Relay Therapeutics made up 0.05% of Prelude Capital Management's portfolio in Q1 2026, its #434 holding.
  • Prelude Capital Management first reported a position in Relay Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Prelude Capital Management's Relay Therapeutics position peaked at $1.22M in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.